An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)

Trial Profile

An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OLSES
  • Sponsors Coherus Biosciences
  • Most Recent Events

    • 29 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 08 Nov 2017 Interim results long-term safety of and durability of response to CHS-0214 in patients who completed Week 48 of trial, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 04 Aug 2017 This trial has been completed in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top